Small RNAs/Functional Genomics
Support and Educational Content

Nanoparticle delivery of TNF-α targeting DsiRNA as treatment for rheumatoid arthritis

te Boekhorst BC, Jensen LB, et al. (2012) MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model. J Control Release, 161(3):772–780.

Current treatment for rheumatoid arthritis (RA), a chronic autoimmune disorder characterized by synovial joint inflammation leading to cartilage destruction, focuses on pain relief rather than complete disease remission. A potential target for securing disease remission is the inflammatory cytokine, tumor necrosis factor-α (TNF-α). TNF-α is produced by macrophages that occur at high abundance in the inflamed membranes and has been shown to influence the progression of synovial damage. Silencing TNF-α expression using small interfering RNA (siRNA) has been explored as a therapeutic strategy for RA treatment. The preferred method of administering siRNA-based therapeutics is by local delivery, which provides direct access to the macrophage cells. The authors evaluate poly(DL-lactic-co-glycolic acid) (PLGA) nanoparticles as a carrier system for efficient delivery of siRNA molecules across the plasma membrane of the macrophages and into the cytosol. Using Dicer-substrate siRNA (DsiRNA; provided by IDT) targeted at TNF-α, they show that DsiRNA-loaded PLGA nanoparticles mediate dose-dependent silencing of TNF-α in vitro. They also demonstrate the effectiveness of using MRI to monitor disease progression by showing reduction of disease activity in vivo.

siRNAs with increased potency

Use IDT DsiRNAs to engage the Dicer-processing/RISC-loading mechanisms and get increased silencing potency over traditional siRNAs.

Learn more ≫

Related Articles

RNAi and DsiRNA: Pathway, Mechanism, and Design

An overview of the RNA interference (RNAi) pathway, its applications, and design considerations for gene silencing experiments.

Read more ≫

Using Antisense Technologies to Modulate Noncoding RNA Function

Useful modifications and design considerations for effective antisense oligonucleotides.

Read more ≫

Small RNA Therapies for Cystic Fibrosis

DsiRNAs are used to develop a protocol for efficient small RNA delivery into airway epithelia to study of miRNA regulation of airway fluid and electrolyte transport.

Read more ≫

Using DsiRNA to Map Pain Pathways in the CNS

Canadian laboratory targets pain receptors for expression knock out via in vivo delivery of DsiRNA 27mer duplex RNAs into the mouse CNS.

Read more ≫

The Future of RNAi and Aptamer Technologies—An Interview with John Rossi

An interview with Dr John Rossi, whose research focuses on the biology and applications of eukaryotic small RNAs and, in particular, their therapeutic use in HIV/AIDS and cancer.

Read more ≫